Infliximab biosimilar
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Infliximab biosimilar, covering 2017-06-20 to 2026-01-06. Get the full timeline:
Most recent: Clinical Trial Update: Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)